– In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab…
Continue ReadingCategoría: Business Wire
Categoría agregada por el Plugin WPeMatico
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
– In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab…
Continue Reading
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of…
Continue Reading
“Experience the Luxury of Japanese Tradition and Cuisine” Reservations for the New Inbound Experience Tour in Osaka’s Tondabayashi Begin on June 1, 2024!
OSAKA, Japan–(BUSINESS WIRE)–The city of Tondabayashi in Osaka is excited to announce a new inbound tour…
Continue Reading
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its…
Continue Reading
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
TORONTO–(BUSINESS WIRE)–Postmedia Network Inc., a wholly owned subsidiary of Postmedia Network Canada Corp. (“Postmedia” or “the…
Continue Reading
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
NEW YORK–(BUSINESS WIRE)–Since 2019, Sally Hansen® has committed to partnering with GLAAD to support Pride and…
Continue Reading
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical…
Continue Reading
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and…
Continue Reading
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement…
Continue Reading